Clinical trial NCT01007019 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: yh4808 30mg, yh4808 50mg, yh4808 100mg, yh4808 200mg, yh4808, yh4808 100mg (repeat dose), yh4808 200mg (repeat dose), yh4808 600mg, yh4808 800mg (single dose), yh4808 400 mg (repeat doses), placebo, esomeprazole 40mg
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male volunteers in the age between 20 to 45 years old

          -  Subjects who were determined to be appropriate through screening

          -  Weight: over 50kg, within ±20% of ideal body weight

          -  Subjects who signed written consent after receiving thorough explanation on trial
             purpose, content, and characteristics of investigational drug

        Exclusion Criteria:

          -  Clinically significant disorder in liver, kidney, cardiovascular, respiratory system,
             endocrine system and CNS in the physical examination and clinical laboratory tests or
             a medical history of malignant tumor or psychological disease

          -  Medical history of gastrointestinal disease or acid restraining surgery,
             gastric/esophagus surgery (excluding appendectomy, hernia surgery)

          -  A history of hypersensitivity to drugs or clinically significant allergic disease

          -  Clinically significant abnormal values in blood chemistry(≥ 1.5 fold of normal upper
             limit in the levels of SGOT, SGPT)

          -  Subjects who were unable to be applicable for pH meter catheter

          -  Subjects who had a history of drug abuse or who had a positive results on urine drug
             screening

          -  Subjects who had taken usual dose of any prescription drugs within 14 days before the
             treatment or who had used usual dose of OTC drugs within 7 days before the
             treatment(cf, be able to be enrolled in this study according to an investigatory
             consideration)

          -  Subjects who participated in another clinical trial within 3 months before enrolling
             in this study

          -  Subjects who donated whole blood within 2 months or component blood within 1 month or
             who are donated within 1 month before the treatment

          -  Subjects who drank Over 21 units/week of alcohol or subjects who weren't able to stop
             drinking alcohol during the hospitalization

          -  Subjects who stopped smoking within 3 months before the treatment

          -  Subjects who had a beverage containing grapefruits within 24hrs before the
             hospitalization or who had a beverage containing grapefruits during the
             hospitalization

          -  Subjects who had a beverage containing caffeine during the hospitalization

          -  H.pylori positive results on the Urease breath test(Only repeat doses)

          -  Subjects with clinically significant observations considered as unsuitable based on
             medical judgment by investigators